Suppression of colonic aberrant crypt foci by soy isoflavones is dose-independent in dimethylhydrazine-treated rats

Journal of Medicinal Food

Volumn 13, Issue 3, 2010, Pages 495-502

  Min, Won Kyung ^a   Sung, Hye Young ^b   Choi, Young Sun ^a  

^a Daegu University   (South Korea)

^b Hallym University   (South Korea)

Author keywords

aberrant crypt foci; colon cancer; cyclooxygenase 2; soy isoflavone

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CYCLOOXYGENASE 2; DAIDZEIN; EQUOL; GENISTEIN; ISOFLAVONE DERIVATIVE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; CRYPT CELL; DIET SUPPLEMENTATION; DOSE RESPONSE; FLUOROIMMUNOASSAY; LIPID PEROXIDATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; DIMETHYLHYDRAZINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION; HUMANS; ISOFLAVONES; MALE; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; SOYBEANS;

ANIMALIA; RATTUS;

EID: 77953802153     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2009.1208     Document Type: Article

References (40)

1. Messina M, Bennink M: Soyfoods, isoflavones and risk of colonic cancer: a review of the in vitro and in vivo data. Baillieres Clin Endocrinol Metab 1998;12:707-728.
2. Bingham SA, Atkinson C, Liggins J, Bluck L, Coward A: Phytooestrogens: where are we now? Br J Nutr 1998;79:393-406.
3. Bayer T, Colnot T, Dekant W: Disposition and biotransformation of the estrogenic isoflavone daidzein in rats. Toxicol Sci 2001;62: 205-211.
4. Munro IC, Harwood M, Hlywka JJ, Stephen AM, Doull J, Flamm WG, Adlercreutz H: Soy isoflavones: a safety review. Nutr Rev 2003;61:1-33.
5. Wang TTY, Sathyamoo N, Phang JM: Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 1996;17:271-275.
6. Magee PJ, Rowland IR: Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr 2004;91:513-531.
7. Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, Tsugane S: Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev 2007;16:538-545. (Pubitemid 46548658)
8. Steiner C, Arnould S, Scalbert A, Manach C: Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics. Br J Nutr 2008;99(E Suppl 1):ES78-ES108.
9. Sarkar FH, Li Y: Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev 2002;21:265-280.
10. Booth C, Hargreaves DF, Hadfield JA, McGown AT, Potten CS: Isoflavones inhibit intestinal epithelial cell proliferation and induce apoptosis in vitro. Br J Cancer 1999;80:1550-1557.
11. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafasson JA: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998;139:4252-4263.
12. Muthyala RS Jr, Ju YH, Sheng S, Williams LD, Doerge DR, Katzenellenbogen S, Helferich WG, Katzenellenbogen JA: Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg Med Chem 2004;12:1559-1567.
13. Rufer CE, Kulling SE: Antioxidant activity of isoflavones and their major metabolites using different in vitro assays. J Agric Food Chem 2006;54:2926-2931.
14. Davis JN, Kucuk O, Djuric Z, Sarkar FH: Soy isoflavone supplementation in healthy men prevents NF-kappaB activation by TNF-alpha in blood lymphocytes. Free Radic Biol Med 2001;30: 1293-1302.
15. Kameoka S, Leavitt P, Chang C, Kuo SM: Expression of antioxidant proteins in human intestinal Caco-2 cells treated with dietary flavonoids. Cancer Lett 1999;146:161-167.
16. Gee JM, Noteborn HPJM, Polley ACJ, Johnson IT: Increased induction of aberrant crypt foci by 1,2-dimethylhydrazine in rats fed diets containing purified genistein or genistein-rich soya protein. Carcinogenesis 2000;21:2255-2259.
17. Daly KT, Tracy AC, Malik M, Wang T, Francke-Carroll S, Magnuson BA: Enhanced estrogenic responses and sensitivity to azoxymethane following dietary soy isoflavone supplementation in older female rats. Food Chem Toxicol 2007;45:628-637.
18. Sung HY, Choi YS: Fructooligosaccharide and soy isoflavone suppress colonic aberrant crypt foci and cyclooxygenase-2 expression in diemethylhyrazine-treated rats. J Med Food 2008;11: 78-85.
19. Thiagarajan DG, Bennink MR, Bourquin LD, Kavas FA: Prevention of precancerous colonic lesions in rats by soy flakes, soy flour, genistein, and calcium. Am J Clin Nutr 1998;68(6 Suppl): S1394-S1399.
20. Guo JY, Li X, Browning JD, Rottinghaus GE, Lubahn DB, Constantinou A, Bennink M, Macdonald RS: Dietary soy isoflavones and estrone protect ovariectomized ERaKO and wild-type mice from carcinogen-induced colon cancer. J Nutr 2004;134: 179-182.
21. American Institute of Nutrition: Report of the Ad Hoc Committee on standards for nutrition studies. J Nutr 1993;123:1939-1951.
22. Bird RP: Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995;93:55-71.
23. Brouwers E, Lhomme R, Al-Maharik N, Lapcik O, Hampl R, Wahala K, Mikola H, Adlercreutz H: Time-resolved fluoroimmunoassay for equol in plasma and urine. J Steroid Biochem Mol Biol 2003;84:577-588.
24. Cho JW, Park K, Kweon GR, Jang BC, Baek WK, Suh MH, Kim CW, Lee KS, Suh SI: Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential upstream targets. Exp Mol Med 2005;37:186-192.
25. Barnes S: Soy isoflavones-phytoestrogens and what else? J Nutr 2004;134:1225S-1228S.
26. MacDonald RS, Guo JY, Copeland J, Browning JD, Sleper D, Rottinghaus GE, Berhow MA: Environmental influence on isoflavones and saponins in soybeans and their role in colon cancer. J Nutr 2005;135:1239-1242.
27. Steele VE, Pereira MA, Sigman CC, Kelloff GJ: Cancer chemoprevention agent development strategies for genistein. J Nutr 1995;125(3 Suppl):713S-716S.
28. Rao CV, Wang C, Simi B, Lubet R, Kelloff GJ, Steele V, Reddy BS: Enhancement of experimental colon cancer by genistein. Cancer Res 1997;57:3717-3722.
29. Raju J, Bielecki A, Caldwell D, Lok E, Taylor M, Kapal K, Curran I, Cooke GM, Bird RP, Mehta R: Soy isoflavones modulate azoxymethane-induced rat colon carcinogenesis exposed pre-and postnatally and inhibit growth of DLD-1 human colon adenocarcinoma cells by increasing the expression of estrogen receptor. J Nutr 2009;139:474-481.
30. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T: Expression of cyclooxygenase- 1 and -2 in human colorectal cancer. Cancer Res 1995; 55:3785-3789.
31. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
32. Harris PJ, Ferguson LR: Dietary fibre: its composition and role in protection against colorectal cancer. Mutat Res 1993;290: 97-110.
33. Sepehr E, Cooke G, Robertson P, Gilani GS: Bioavailability of soy isoflavones in rats. Part I: Application of accurate methodology for studying the effects of gender and source of isoflavones. Mol Nutr Food Res 2007;51:799-812.
34. Kwon SH, Kang MJ, Huh JS, Ha KW, Lee JR, Lee SK, Lee BS, Han IH, Lee MS, Lee MW, Lee J, Choi YW: Comparison of oral bioavailability of genistein and genistin in rats. Int J Pharm 2007;337:148-154.
35. Zhou S, Hu Y, Zhang B, Teng Z, Gan H, Yang Z, Wang Q, Huan M, Mei Q: Dose-dependent absorption, metabolism, and excretion of genistein in rats. J Agric Food Chem 2008;56:8354-8359.
36. Wei H, Wei L, Frenkel K, Bowen R, Barnes S: Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutr Cancer 1993;20:1-12.
37. Heneman KM, Chang HC, Prior RL, Steinberg FM: Soy protein with and without isoflavones fails to substantially increase postprandial antioxidant capacity. J Nutr Biochem 2007;18: 46-53.
38. Vega-Lopez S, Yeum KJ, Lecker JL, Ausman LM, Johnson EJ, Devaraj S, Jialal I, Lichtenstein AH: Plasma antioxidant capacity in response to diets high in soy or animal protein with or without isoflavones. Am J Clin Nutr 2005;81:43-49.
39. Williamson G, Barron D, Shimoi K, Terao J: In vitro biological properties of flavonoid conjugates found in vivo. Free Radic Res 2005;39:457-479.
40. Cooke GM: A review of the animal models used to investigate the health benefits of soy isoflavones. J AOAC Int 2006;89: 1215-1227.